Hepatitis Treatment News : High Cure Rates From Sofosbuvir, Ribavirin for Genotypes 2 & 3
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis Treatment News » November 2013


emailprint

November 5, 2013

High Cure Rates From Sofosbuvir, Ribavirin for Genotypes 2 & 3

Gilead’s sofosbuvir boasted high cure rates when given in combination with ribavirin to those with genotype 2 or 3 of hepatitis C virus (HCV). Representatives for the pharmaceutical company presented findings from the Phase III VALENCE trial at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC.

Seventy-three participants with genotype 2 took the nucleotide polymerase inhibitor sofosbuvir and ribavirin for 12 weeks, and 250 with genotype 3 took the regimen for 24 weeks. About 20 percent of the study group had cirrhosis.

Ninety-three percent of the genotype 2 participants and 85 percent of the genotype 3 participants achieved a sustained virologic response 12 weeks after completing therapy (an SVR, considered a cure).

Among the treatment-naive participants with genotype 2, 97 percent (29/30) of those without cirrhosis and 100 percent (2/2) of those with cirrhosis achieved a cure; in the treatment-experienced sub-group, 91 percent (30/33) of those without cirrhosis and 88 percent (7/8) of those with cirrhosis achieved a cure.

As for genotype 3 participants, among the treatment-naive, 94 percent (86/92) of those without cirrhosis and 92 percent (12/13) of those with cirrhosis achieved a cure; in the treatment-experienced sub-group, 87 percent (87/100) of those without cirrhosis and 60 percent (27/45) of those with cirrhosis achieved a cure.

The most common side effects included headache, fatigue, itching, weakness and lack of energy, nausea and insomnia.

To read a Gilead release, click here.

Search: Sofosbuvir, Gilead, hepatitis C, hep C, HCV, genotype 2, genotype 3, VALENCE, 64th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD, cirrhosis.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Are you planning to do anything for World Hepatitis Day on July 28?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.